Inactive Instrument

GW Pharmaceuticals plc Stock London S.E.

GB0030544687

Biotechnology & Medical Research

End-of-day quote London S.E. Other stock markets
- ^GBX	-

21-08-12	Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	RE
21-08-10	Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	MT

Latest news : GW Pharmaceuticals plc

21-08-12	Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	RE
21-08-10	Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	MT
21-08-10	Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug	MT
21-08-10	Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	CI
21-06-17	Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy	MT
21-06-17	Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase	MT
21-05-26	Palla Pharma : Names New CEO; Shares Soar 18%	MT
21-05-10	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index	CI
21-05-05	Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals	MT
21-05-04	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index	CI
21-05-04	Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc.	CI
21-05-03	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index	CI
21-05-03	Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021	CI

More news

Analysts' recommendations: GW Pharmaceuticals plc

21-02-04	GW PHARMACEUTICALS : SVB Leerink Downgrades GW Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $220 from $200	MT
21-02-04	GW PHARMACEUTICALS : Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $220 From $193	MT
21-02-04	GW PHARMACEUTICALS : HC Wainwright Downgrades GW Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $220 From $162	MT
21-02-03	GW PHARMACEUTICALS : Needham Downgrades GW Pharmaceuticals to Hold from Buy	MT
20-12-29	GW PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on GW Pharmaceuticals to $147 From $165, Maintains Overweight Rating	MT

More recommendations

Press Releases: GW Pharmaceuticals plc

23-04-06	Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	AQ
23-01-23	Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor	AQ
22-03-28	Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	AQ
22-03-02	JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS	AQ
21-05-12	Alkame : PAO Group, Inc.'s CBD Nutraceuticals Expected To Deliver Revenue-Generating Catalyst in 2021; New Partnerships Expand Its Long-Term CBD Pharmaceutical Programs	AQ

More press releases

News in other languages: GW Pharmaceuticals plc

21-07-06	HINTERGRUND/Bei Pharma-Übernahmen schlagen inzwischen oft Midcaps zu
21-02-04	Planète Bourse : La revue de presse du jeudi 4 févier 2021
21-02-04	EN DIRECT DES MARCHES : Dassault Systèmes, Carrefour, Stellantis, Air France-KLM, Daimler, PayPal, Roche, Nokia...
21-02-04	Des marchés en pause sous un déluge de résultats
21-02-03	MÄRKTE USA/Erholung verliert an Fahrt - Alphabet-Aktie mit Rekordhoch

More news

Managers and Directors: GW Pharmaceuticals plc

Manager	Title	Age	Since
Alkesh Patel SEC	Corporate Secretary	-	2024-04-02

Director	Title	Age	Since
Amanda Flanagan BRD	Director/Board Member	55	2025-02-09
David Spackman BRD	Director/Board Member	50	2023-01-12

More insiders

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	-4.14%	-8.06%	+57.35%	+117.24%	54.63B
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+75.79%	+93.87%	54.88B
INSMED INCORPORATED	-2.24%	+3.59%	+19.60%	+466.72%	25.06B
BIONTECH SE	-1.60%	-6.21%	-19.69%	-14.84%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+47.70%	-0.11%	19.88B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
EXELIXIS, INC.	-1.05%	+1.16%	+25.08%	+196.28%	14.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+53.81%	-	15.36B
Average	-0.67%	-0.28%	+54.31%	+148.68%	26.8B
Weighted average by Cap.	-0.91%	-1.46%	+55.04%	+137.79%

GW Pharmaceuticals plc Stock London S.E.

Stocks

GB0030544687

Biotechnology & Medical Research

Latest news : GW Pharmaceuticals plc

Analysts' recommendations: GW Pharmaceuticals plc

Press Releases: GW Pharmaceuticals plc

News in other languages: GW Pharmaceuticals plc

Managers and Directors: GW Pharmaceuticals plc

Bio Therapeutic Drugs

Company Profile